Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06424288 · ClinicalTrials.gov registry record · Phase 3

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

A Phase 3 study of Heart Failure, sponsored by Boehringer Ingelheim.

Recruiting
Registry status
Phase 3
Development phase
6,000
Enrollment target
20
Study locations

NCT06424288: Recruiting Phase 3 study of Heart Failure, sponsored by Boehringer Ingelheim.

NCT06424288 is a Phase 3 study of Heart Failure that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 6,000 participants, above the 2,034-participant average among 397 other Heart Failure trials with a reported enrollment target (195% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06424288, a Phase 3 study of Heart Failure, is actively recruiting participants, sponsored by Boehringer Ingelheim.

RECRUITING
Registry status
Phase 3
Development phase
6,000 participants
Enrollment target
20
Study locations

Study Summary

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The study does not have a fixed duration. It continues until there is enough data to see if the treatment is working.

Conditions Studied

Heart Failure

Interventions

  • DRUG placebo
  • DRUG vicadrostat
  • DRUG empagliflozin

Study Locations (20)

Florida

  • Excel Medical Clinical Trials - Boca Raton
  • Bay Area Cardiology - Brandon
  • Clearwater Cardiovascular and Interventional Consultants - Clearwater
  • Cardiology Associates Research Co. - Daytona Beach
  • Malcom Randall VA Medical Center - Gainesville
  • Velocity Clinical Research-Hallandale Beach-67888 - Hallandale
  • University of Florida Health Jacksonville - Jacksonville
  • East Coast Institute for Research, LLC - Jacksonville - Jacksonville
  • East Coast Institute for Research, LLC - Jacksonville - Jacksonville
  • First Coast Cardiovascular Institute - Jacksonville
  • Clearwater Cardiovascular Consultants-Largo-69917 - Largo
  • University of Miami - Miami

California

  • Velocity Clinical Research-Chula Vista - Chula Vista
  • University of California Irvine - Orange
  • North America Research Institute - San Dimas
  • Amicis Research Center - Valencia - Santa Clarita
  • Orange County Research Center - Tustin

Alabama

  • Diagnostic and Medical Clinic - Mobile
  • Mobile Heart Specialists, PC - Mobile

Connecticut

  • Bridgeport Hospital - Bridgeport

Trial Details

FieldValue
Enrollment Target 6,000 participants
Start Date 2024-06-17
Est. Completion 2028-05-22
Phase Phase 3
Boehringer Ingelheim

515 total trials

What NCT06424288 shows while recruiting

NCT06424288 is an interventional study that assigns participants to a tested intervention. Its 6,000 participants enrollment target places it among the larger protocols in the corpus, above the 2,034-participant average among 397 other Heart Failure trials with a reported enrollment target (195% higher).

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.

NCT06424288 names 20 study sites across 4 states, led by Florida, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT06424288 about?

NCT06424288 is a clinical study titled "A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure". This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empag...

What is the current status of trial NCT06424288?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 6,000 participants. The study started on 2024-06-17. Estimated completion is 2028-05-22.

What conditions does trial NCT06424288 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT06424288?

The interventions under investigation include: placebo (DRUG), vicadrostat (DRUG), empagliflozin (DRUG).

Who is sponsoring clinical trial NCT06424288?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06424288 being conducted?

This trial has 20 study locations across Alabama, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06424288's enrollment target sits among peer trials

6,000 12th of 397 higher than 385 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00005095 · 6,000 participants

    Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

  • NCT00280202 · 6,000 participants

    Detection of Genetic Markers of Lung Cancer

  • NCT03127631 · 6,000 participants · NA

    A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

  • NCT03539705 · 6,000 participants

    Food Allergy Registry at a Single Site

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06424288

Source: ClinicalTrials.gov NCT06424288, the US trial registry maintained by the National Library of Medicine. NCT06424288 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.